| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
Purity: ≥98%
CWP232228 sodium is a novel and selective Wnt/β-Catenin inhibitor that antagonizes binding of β-catenin to T-cell factor (TCF) in the nucleus. It preferentially inhibits the growth of breast cancer stem-like cells. CWP232228 targets liver cancer stem cells through Wnt/β- a novel therapeutic approach for liver cancer treatment.
| ln Vitro |
CWP232228 (0.01-100 μM; 48 hours) suppresses cell growth with IC50 values of 2 and 0.8 μM in mouse (4T1) and human (MDA-MB-435) breast cancer cell lines, respectively [1]. CWP232228 (0.01-10 μM; 48 hours) suppresses cell growth in Hep3B, Huh7, and HepG2 cells with IC50 of 2.566, 2.630, and 2.596 μM, respectively [2].
|
|---|---|
| ln Vivo |
Tumor volume was significantly reduced by CWP232228 (100 mg/kg, i.p.; daily; 21 days for mice with 4T1 cell tumors; 60 days for mice with MDA-MB-435 cell tumors) [1].
|
| Cell Assay |
Cell proliferation assay[1]
Cell Types: mouse (4T1) and human (MDA-MB-435) Breast cancer cell lines Tested Concentrations: 0.01, 0.1, 1, 10, 100 μM Incubation Duration: 48 hrs (hours) Experimental Results: IC50 is 2 respectively and 0.8 μM for 4T1 and MDA-MB-435 cell lines respectively. Cell proliferation assay [2] Cell Types: Hepatoma cell lines HepG2, Huh7 and Hep3B Tested Concentrations: 0.01, 0.1, 0.5, 1, 5, 10 μM Incubation Duration: 48 hrs (hours) Experimental Results: IC50 are 2.566, 2.630 and 2.596 μM respectively for Hep3B , Huh7 and HepG2 cells. |
| Animal Protocol |
Animal/Disease Models: 7weeks old female Balb/c and NOD/SCID (severe combined immunodeficient) mouse harboring 4T1 or MDA-MB-435 cell tumors [1]
Doses: 100 mg/kg Route of Administration: intraperitoneal (ip) injection; daily; for 4T1 cell-bearing tumors It was 21 days for mice with tumors and 60 days for mice with MDA-MB-435 cell tumors. Experimental Results: Treatment resulted in a significant reduction in tumor volume. |
| References |
|
| Molecular Formula |
C33H34N7NA2O7P
|
|---|---|
| Molecular Weight |
717.619069576263
|
| Exact Mass |
717.205
|
| CAS # |
1144044-02-9
|
| Related CAS # |
1144044-02-9 (sodium);1144045-59-9 (free acid);
|
| PubChem CID |
71509158
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
50
|
| Complexity |
1210
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
P(=O)([O-])([O-])OC1C=CC(=CC=1)C[C@H]1C(N(CC2=CC=CC3=CN(C)N=C23)C[C@@H]2N(C(NCC3C=CC=CC=3)=O)N(CC=C)CC(N21)=O)=O.[Na+].[Na+]
|
| InChi Key |
KKMKZLQVDAGSOA-GDUXWEAWSA-L
|
| InChi Code |
InChI=1S/C33H36N7O7P.2Na/c1-3-16-38-22-30(41)39-28(17-23-12-14-27(15-13-23)47-48(44,45)46)32(42)37(20-26-11-7-10-25-19-36(2)35-31(25)26)21-29(39)40(38)33(43)34-18-24-8-5-4-6-9-24/h3-15,19,28-29H,1,16-18,20-22H2,2H3,(H,34,43)(H2,44,45,46)/q2*+1/p-2/t28-,29-/m0../s1
|
| Chemical Name |
Sodium
4-(((6S,9aS)-2-Allyl-1-(benzylcarbamoyl)-8-((2-methyl-2H-indazol-7-yl)methyl)-4,7-dioxooctahydro-2H-pyrazino[2,1-c][1,2,4]triazin-6-yl)methyl)phenyl
phosphate
|
| Synonyms |
CWP232228 CWP-232228 CWP 232228 CWP232228 sodium,
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~62.5 mg/mL (~87.09 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (69.67 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3935 mL | 6.9675 mL | 13.9350 mL | |
| 5 mM | 0.2787 mL | 1.3935 mL | 2.7870 mL | |
| 10 mM | 0.1393 mL | 0.6967 mL | 1.3935 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA